U.S. Biomarker Test Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Biomarker Test Market
- ✓Market Size 2024: USD 18.6 billion
- ✓Market Size 2032: USD 38.9 billion
- ✓CAGR: 9.8%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Prioritize Coverage Evidence Now: Diagnostics developers must file MolDX technical assessment submissions before the end of 2026, using real-world utilization data from oncology practices. Early MolDX coverage determines which commercial payers follow, so delay forfeits the reimbursement window for next-generation sequencing panels.
Biomarker Testing in the United States: Market Overview
The U.S. biomarker test market was valued at USD 18.6 billion in 2024 and is projected to reach USD 38.9 billion by 2032, growing at a 9.8% CAGR. Oncology accounts for the largest share, with companion diagnostics and next-generation sequencing panels delivered through reference laboratories such as Labcorp and Quest Diagnostics alongside specialist firms including Foundation Medicine and Guardant Health. The structure is hybrid: private laboratories and developers lead commercial innovation, while federal bodies set the rules of entry and payment.
Government has been the dominant force in shaping demand through the Clinical Laboratory Improvement Amendments of 1988, administered by CMS with the CDC, which set analytical quality standards for every testing laboratory. Medicare coverage determinations then set reimbursement levels that define commercial viability. The private sector has led platform development, with Illumina and Thermo Fisher Scientific supplying sequencing infrastructure and Tempus AI building data-linked testing services.
Policy-Driven Growth in U.S. Biomarker Testing
The 21st Century Cures Act of 2016 funded the Cancer Moonshot with USD 1.8 billion over seven years, channelled through the National Cancer Institute. This money built biomarker-driven trial infrastructure, so trial-linked testing flowed to commercial laboratories. Medicare National Coverage Determination 90.2, effective 2018, covers next-generation sequencing for beneficiaries with advanced cancer, which guarantees payment volume for oncology panels.
Medicare Administrative Contractor coverage through the MolDX program, operated by Palmetto GBA, issues Local Coverage Determinations for multi-biomarker panels, translating technical assessment into payer-wide reimbursement. Each determination converts a laboratory's validated test into a billable service across participating states. Together, these three mechanisms convert research spending and clinical evidence into predictable revenue, which attracts capital into test development.
Regulatory Barriers and Compliance Costs
Every laboratory performing biomarker tests on human specimens must hold a CLIA certificate from CMS, with the CDC providing technical guidance on proficiency testing. New York State adds a further barrier: the Department of Health's Clinical Laboratory Evaluation Program requires a separate permit before a laboratory can test specimens from New York patients. Permit reviews routinely extend market entry by several months and add substantial compliance cost for national laboratories.
Reimbursement compression presents the second barrier. Under the Protecting Access to Medicare Act of 2014, CMS sets Clinical Laboratory Fee Schedule rates using private payer data, and statutory reductions are capped at 15% per year. Laboratories without scale absorb these cuts, while the Federal Food, Drug, and Cosmetic Act and FDA oversight add validation burdens for companion diagnostics.
Policy-Created Opportunities in U.S. Biomarker Testing
The CMS Transitional Coverage for Emerging Technologies pathway offers coverage to designated breakthrough devices before traditional national coverage is settled. Developers holding FDA Breakthrough Device designation can access this route, which accelerates revenue for novel multi-cancer and minimal residual disease assays. Early enrollment in this pathway provides a reimbursement advantage over competitors awaiting standard determinations.
The Department of Veterans Affairs Million Veteran Program offers a large, consented genomic cohort that supports validation studies and procurement contracts with federal health systems. Laboratories that partner with VA medical centers gain access to a captive patient population with high cancer incidence. The All of Us Research Program, funded through the Cures Act, similarly creates validated datasets for pharmacogenomic and biomarker test development.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 18.6 billion |
| Market Size 2032 | USD 38.9 billion |
| Growth Rate (CAGR) | 9.8% |
| Most Critical Decision Factor | Payer coverage determination under MolDX and NCD 90.2 |
| Largest Region | Northeast and Mid-Atlantic corridor |
| Competitive Structure | Consolidated laboratory leaders with fragmented specialist firms |
Leading Market Participants
- Labcorp
- Quest Diagnostics
- Natera
- Guardant Health
- Foundation Medicine
- Myriad Genetics
- Exact Sciences
- Illumina
- Tempus AI
- Caris Life Sciences
Regulatory and Policy Environment
The primary legislation is the Clinical Laboratory Improvement Amendments of 1988, administered by CMS with CDC support, which requires CLIA certification, proficiency testing, and quality control for every laboratory. The FDA's final rule on laboratory developed tests, issued in May 2024, was vacated by the U.S. District Court for the Eastern District of Texas in March 2025 in American Clinical Laboratory Association v. FDA. Laboratory developed tests therefore remain outside FDA premarket review, and the Federal Food, Drug, and Cosmetic Act governs only FDA-cleared or approved devices.
Upcoming changes centre on the Medicare Clinical Laboratory Fee Schedule, updated annually under PAMA, with rate effects taking hold each January 1. Congressional proposals to create federal LDT oversight, including successors to the VALID Act, remain under review without enactment. Against regional peers, the U.S. framework is more permissive than the European Union's In Vitro Diagnostic Regulation (EU) 2017/746, whose transition deadlines run through 2027 and 2029 and impose full conformity assessment on laboratory tests.
Long-Term Policy Outlook for U.S. Biomarker Testing
By 2032, payer-led coverage will be the principal regulatory mechanism for biomarker testing, with MolDX determinations and NCD 90.2 shaping which panels reach patients. Expect PAMA reform to remain a central legislative issue, since reimbursement compression determines which laboratories survive consolidation. Federal LDT oversight will stay contested, so laboratories will carry the compliance burden of analytical validation regardless of FDA's formal authority.
The market will reshape around laboratories that combine scale with validated real-world evidence. Companies able to satisfy MolDX technical assessment and CLIA requirements across all states will gain share, while smaller specialist firms will need partnerships or acquisition. Policy direction therefore points toward concentration, with reimbursement evidence becoming the decisive competitive asset through the forecast period.
Frequently Asked Questions
Market Segmentation
- Next-Generation Sequencing Panels
- Companion Diagnostics
- Immunohistochemistry Assays
- Liquid Biopsy Tests
- Pharmacogenomic Tests
- Oncology
- Cardiovascular Disease
- Neurology
- Infectious Disease
- Reference Laboratories
- Hospital Laboratories
- Academic Medical Centers
- Pharmaceutical Companies
- Federal Health Systems
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.